Home  »  Finance   »  Who is the Top Investor In Ocular Therapeutix Inc....

Who is the Top Investor In Ocular Therapeutix Inc. (OCUL)?

Ocular Therapeutix Inc. (NASDAQ: OCUL) is -56.81% lower on its value in year-to-date trading and has touched a low of $2.77 and a high of $7.39 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The OCUL stock was last observed hovering at around $2.95 in the last trading session, with the day’s gains setting it 0.06%.

Currently trading at $3.01, the stock is -8.93% and -26.69% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.32 million and changing 2.03% at the moment leaves the stock -32.07% off its SMA200. OCUL registered -54.60% loss for a year compared to 6-month gain of -1.63%.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


The stock witnessed a -18.21% loss in the last 1 month and extending the period to 3 months gives it a -45.67%, and is -1.63% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.90% over the week and 6.64% over the month.

Ocular Therapeutix Inc. (OCUL) has around 228 employees, a market worth around $230.30M and $49.70M in sales. Distance from 52-week low is 8.66% and -59.27% from its 52-week high. The company has generated returns on investments over the last 12 months (-56.00%).

Ocular Therapeutix Inc. (OCUL) Analyst Forecasts

Ocular Therapeutix Inc. is expected to release its quarterly report on 03/09/2023.The EPS is expected to grow by 96.70% this year

Ocular Therapeutix Inc. (OCUL) Top Institutional Holders

The shares outstanding are 76.98M, and float is at 76.10M with Short Float at 4.38%.

Ocular Therapeutix Inc. (OCUL) Insider Activity

A total of 12 insider transactions have happened at Ocular Therapeutix Inc. (OCUL) in the last six months, with sales accounting for 0 and purchases happening 12 times. The most recent transaction is an insider purchase by SUMMER ROAD LLC, the company’s 10% Owner. SEC filings show that SUMMER ROAD LLC bought 7,328 shares of the company’s common stock on Nov 07 at a price of $3.50 per share for a total of $25648.0. Following the purchase, the insider now owns 6.12 million shares.

Ocular Therapeutix Inc. disclosed in a document filed with the SEC on Oct 11 that SUMMER ROAD LLC (10% Owner) bought a total of 10,000 shares of the company’s common stock. The trade occurred on Oct 11 and was made at $3.90 per share for $38993.0. Following the transaction, the insider now directly holds 6.11 million shares of the OCUL stock.

Still, SEC filings show that on Oct 10, SUMMER ROAD LLC (10% Owner) acquired 10,000 shares at an average price of $4.00 for $39982.0. The insider now directly holds 6,104,761 shares of Ocular Therapeutix Inc. (OCUL).

Ocular Therapeutix Inc. (OCUL): Who are the competitors?

The company’s main competitors (and peers) include KalVista Pharmaceuticals Inc. (KALV) that is trading -66.79% down over the past 12 months and Anika Therapeutics Inc. (ANIK) that is -24.89% lower over the same period.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.